Programmed death ligand-1 expression in non-small cell lung cancer.
about
PD-L1 expression in human cancers and its association with clinical outcomesTowards tumor immunodiagnosticsA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingEpstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune ResponsePredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisAdvances in immunotherapy for treatment of lung cancerDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerPredictive biomarkers in precision medicine and drug development against lung cancerTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsImmunotherapy in the treatment of non-small cell lung cancerPD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined SubgroupsPrognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsProspects of immune checkpoint modulators in the treatment of glioblastomaPD-L1 and Survival in Solid Tumors: A Meta-AnalysisClinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung CancerAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerAn Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.Programmed cell death ligand 1 expression in osteosarcoma.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerPD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.Nivolumab in NSCLC: latest evidence and clinical potentialMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor typesEBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
P2860
Q26738361-E28D13F4-D6B5-40BA-BA29-4A576F6755F6Q26738691-C0BC1E3C-8C5E-4B37-8BCB-A0F60783CFC3Q26738729-D98B804A-1B96-425C-A9A0-B8B91A8C0F6EQ26741101-4846E77A-2A76-4D77-A56E-F6218D6E2458Q26745516-BBBECAEC-6D57-44BE-8FBA-8C97D65FE62BQ26747792-700D5665-5102-4253-B088-170BDC93C27EQ26751029-5B38A93E-CAD9-4EEB-8120-40E2F7D624BCQ26769728-912C6066-4DC1-4DE1-9028-9813DBBFF4EAQ26778790-CD3E013C-00AE-41EA-8D14-5F1CB32DC2C9Q26798047-4F182119-93B4-4463-9669-DBA6BE2ABBDAQ26824536-C4825B89-6268-46F9-9E96-D84998899E56Q26996518-7B8EFD50-B8C8-46C9-94B8-8B2470EC758FQ27000382-A7B2CFC0-E544-4DEF-A021-C0E7B520F45EQ27853205-4941FE75-E47A-4AF4-916D-0E7E744D2CBFQ27853291-2A1BFA91-B3DC-4706-BE4F-019E1CF74431Q28075712-F9A25EDE-A63C-4834-A2D5-53B1DDC455F7Q28081371-62ECF80E-C288-4F1F-9066-6995C5F77E45Q28084090-9483BB24-72AF-460D-AA59-6A675C017270Q28084766-A2B90B5B-354C-4BA1-A219-D43A999841A2Q29617774-37B818D5-6C47-466A-A062-190E63A08EA8Q29620902-925676EE-4899-424E-A79B-9558832A4375Q30489890-94A9FF17-6AD2-4B95-8A2E-84917FB4944BQ31137039-B763B2ED-D3D9-47CF-9785-125D50D39187Q33586463-C9EE5421-59F2-41D7-80B2-B8DDA1AC6D63Q33607407-A5D3E6A0-16E9-44C3-82D1-E2C971276B1FQ33644049-16211F2F-E2E8-4C0F-9E5E-9FA9C5FA92E3Q33658400-1EBC78B8-05E2-49DB-A08B-AA9A74318707Q33688849-B4B9F9A3-D998-468C-933F-98F922CB7288Q33788049-DA041066-890A-46B2-8CE0-92BCD710B8E6Q33848154-65455497-93BB-43F5-AABA-DD7ED10ECF50Q34270064-BC04EAFE-61A9-490F-BEEA-8A6C06056601Q34454922-815E6A78-EB81-4E49-8361-F56BD9F4AC5AQ34466452-C55B5283-0530-46D7-8A69-97DB44E2C545Q34522172-B77FA4A9-800C-4650-BF1E-545D8DFCC100Q34623884-6101CDC8-C9BA-4E44-89C7-C7E20CF1C498Q34669751-04842D87-61AA-4EC3-A36E-DA3A067EB941Q35067875-EBABF55F-64EC-4B9E-A620-7E7DC5B94D34Q35143602-955F5CA2-E622-4F74-8ACB-AD50FC193988Q35182037-E7A2D2F9-6C6F-47B3-8A1C-372E779A8FA2Q35256558-B0E35AEA-10B9-4100-84E0-62F8B99DA59F
P2860
Programmed death ligand-1 expression in non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Programmed death ligand-1 expression in non-small cell lung cancer.
@ast
Programmed death ligand-1 expression in non-small cell lung cancer.
@en
Programmed death ligand-1 expression in non-small cell lung cancer.
@nl
type
label
Programmed death ligand-1 expression in non-small cell lung cancer.
@ast
Programmed death ligand-1 expression in non-small cell lung cancer.
@en
Programmed death ligand-1 expression in non-small cell lung cancer.
@nl
prefLabel
Programmed death ligand-1 expression in non-small cell lung cancer.
@ast
Programmed death ligand-1 expression in non-small cell lung cancer.
@en
Programmed death ligand-1 expression in non-small cell lung cancer.
@nl
P2093
P2860
P50
P1476
Programmed death ligand-1 expression in non-small cell lung cancer.
@en
P2093
Daniel E Carvajal
David L Rimm
Konstantinos N Syrigos
Lieping Chen
Scott N Gettinger
Valsamo K Anagnostou
Vamsidhar Velcheti
P2860
P2888
P304
P356
10.1038/LABINVEST.2013.130
P577
2013-11-11T00:00:00Z
P5875
P6179
1024707845